Oculus Innovative Sciences Announces Fiscal First Quarter 2015 Financial Results and Conference Call Jul 24, 2014
Oculus Innovative Sciences Reports Revenues of $2.9 Million and Net Income of $7.5 Million for Fourth Quarter of Fiscal 2014 Primarily Due to Accounting Treatment of Ruthigen IPO Transaction Jun 12, 2014
Oculus Innovative Sciences Announces Fiscal Fourth Quarter 2014 Financial Results and Conference Call May 29, 2014
Oculus Innovative Sciences' Partner, More Pharma, Launches Microcyn(R)-Based Oral and Throat Infection Treatment Product in Mexico Apr 22, 2014
Oculus Innovative Sciences Receives 'Strong Consensus' Rating for Use With Kinetic Concepts' Negative Pressure Wound Therapy With Instillation Apr 9, 2014
Oculus Innovative Sciences Announces Board of Directors Restructuring Following Ruthigen IPO Apr 2, 2014
Oculus Innovative Sciences Announces Appointment of Sharon Barbari to Its Board of Directors Mar 27, 2014
Oculus Innovative Sciences Announces Appointment of Russell Harrison to Board of Directors Feb 27, 2014
Oculus Innovative Sciences Receives Approval for Oral and Throat Infection Products in Mexico Feb 19, 2014
